Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis

Chang SS (2004) Overview of prostate-specific membrane antigen. Rev Urol 6:S13–S16

Pinto JT, Suffoletto BP, Berzin TM et al (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2:1445–1451

Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261

Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwendt JE, Kuefer R, Rubin MA (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696–701

Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 7:927–936

Moreno JG, Croce CM, Fischer R et al (1992) Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 52:6110–6112

Silver DA, Pellicer I, Fair WL et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissue. Clin Cancer Res 3:81–85

Chang S, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD Gaudin PB (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681

Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334

Gleason DF (1977) Histologic grading and clinical staging of prostatic carcinoma. In: Tannebaum M (ed) Urologic pathology: the prostate. Lea & Febiger, Philadelphia, pp 171–197

Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R (2006) Current practice of Gleason grading of prostate carcinoma. Virchows Arch 448(2):111–118

Douglas G. Altman: Practical Statistics for Medical Research Chapman & Hall/CRC 1 edition (November 22, 1990)

Bander NH (2006) Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3(4):216–225

Sodee DB, Sodee AE, Bakale G (2007) Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 37(1):17–28

Elsässer-Beile U, Wolf P, Gierschner D, Bühler P, Schultze-Seemann W, Wetterauer U (2006) A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66(13):1359–1370

Ross JS, Sheehan CHE, Fisher HAG, Kaufman RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BVS (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357–6362

Zhigang Z, Wenly S (2004) Prostate stem cell antigen (PSCA) expression in human prostate cancer tissue and its potential role in prostate carcinogenesis and progression of prostate cancer. W J Surg Oncol 2:1–13

Bühler P, Wolf P, Gierschner D, Schabel I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U (2008) A bispecific diabody directed against prostate-specific membrane antigen and CD33 induces T-cell mediated lysis of prostate cancer cells. Can Immunol Immunother 57(1):43–52